ClinicalTrials.gg
CompletedNCT05917938Updated Feb 11, 2026

A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

A Phase 1 interventional study of NNC0194-0499 in Hepatic Impairment and Healthy Volunteers, sponsored by Novo Nordisk A/S. Completed at 5 sites in 3 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The study medicine NNC0194-0499 is under development for non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH). All participants will receive a single dose of 30 milligram (mg) of the study medicine. The study medicine will be given in the form of an injection of 0.6 millilitres in a skinfold of the thigh (subcutaneous). The study will last for up to 64 days. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period. Women who are able to become pregnant must use highly effective contraception and will be counselled on the use of contraception. Participants with impaired liver function will undergo an ultrasound of the belly and measurement of brain activity.

02

Conditions studied

  • Hepatic Impairment
  • Healthy Volunteers
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Aged 18-80 years (both inclusive) at the time of signing .
  • (BMI) between 18.5-39.9 kilogram per square meter (kg/m\^2) (both inclusive). Specific inclusion criterion only for participants with hepatic impairment:
  • Participants with stable hepatic impairment classified as grade A, B or C as assessed by the investigator. Stable hepatic impairment is defined as no change in disease status, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products.
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using a highly effective method.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Participants With Normal Hepatic Function

    Participants with normal hepatic function will receive a single subcutaneous dose of 30 milligram (mg) of NNC0194-0499 on Day 1.

    Drug: NNC0194-0499

  • Experimental
    Participants With Mild Hepatic Impairment

    Participants with mild hepatic impairment (Child Pugh Grade A) will receive a single subcutaneous dose of 30 mg of NNC0194-0499 on Day 1.

    Drug: NNC0194-0499

  • Experimental
    Participants With Moderate Hepatic Impairment

    Participants with moderate hepatic impairment (Child-Pugh Grade B) will receive a single subcutaneous dose of 30 mg of NNC0194-0499 on Day 1.

    Drug: NNC0194-0499

  • Experimental
    Participants With Severe Hepatic Impairment

    Participants with severe hepatic impairment (Child-Pugh Grade C) will receive a single subcutaneous dose of 30 mg of NNC0194-0499 on Day 1.

    Drug: NNC0194-0499

Interventions

  • NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.

06

What researchers measure

Primary outcomes

  1. AUC0-∞, Single Dose, NNC0194-0499: the area under the NNC0194-0499 serum concentration-time curve from time 0 to infinity after a single dose

    Measured in nanomoles hour per liter (nmol h/L).

    Time frame: From 0 hours (Day 1) until end of study visit (Day 36)

Secondary outcomes

  1. Cmax, NNC0194-0499: the maximum concentration of NNC0194-0499 in serum

    Measured in nanomoles per liter (nmol/L).

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  2. tmax, NNC0194-0499: the time from dose administration to maximum serum concentration of NNC0194-0499

    Measured in hours.

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  3. t1/2, NNC0194-0499: the terminal half-life of NNC0194-0499 in serum

    Measured in hours.

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  4. CL/F, NNC0194-0499: the apparent total serum clearance of NNC0194-0499

    Measured in liters per hour.

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  5. Vz/F, NNC0194-0499: apparent volume of distribution of NNC0194-0499 after a single dose

    Measured in liters.

    Time frame: From Day 1 (pre-dose) until completion of the end of trial visit (Day 36)

  6. Number of treatment emergent adverse events (TEAEs)

    Measured as number of events.

    Time frame: From time of trial product administration (Visit 2, Day 1) until completion of the end of trial visit (Visit 8, Day 36)

07

Study locations

5 sites
  • APEX Research
    München, 81241, Germany
  • Uniwersyteckie Centrum Kliniczne (UCK)
    Gdansk, 80-214, Poland
  • Cardiomedicum Sp. z o.o.
    Krakow, 30-002, Poland
  • Summit Clinical Research s.r.o.
    Bratislava, 83101, Slovakia
  • Summit Clinical Research s.r.o.
    Malacky, 901 22, Slovakia
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Dec 2024, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2023
First posted
Jun 26, 2023
StartActual
Jul 4, 2023
Primary completionActual
Dec 16, 2024
CompletionActual
Dec 16, 2024
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05917938
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 26, 2023
Start date
Jul 4, 2023
Primary completion
Dec 16, 2024
Completion
Dec 16, 2024
Last update
Feb 11, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zalfermin

Start the discussion